Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications
Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study.
Journal: Vaccines
Published: April 03, 2026
Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive.
Journal: Infectious diseases and therapy
Published: January 23, 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine.
Journal: NPJ vaccines
Published: December 18, 2025
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals.
Journal: Virus evolution
Published: May 21, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.
Journal: Infectious diseases and therapy
Published: March 07, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines.
Journal: Nature communications
Published: November 06, 2024
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.
Journal: Vaccine
Published: September 30, 2024
Mitigating the surge of mpox in Africa: capacity building through public outreach, sample and case management training for healthcare workers and veterinarians.
Journal: The Pan African medical journal
Published: June 30, 2024
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.
Journal: NPJ vaccines
Published: May 06, 2024
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.
Journal: Vaccines
Published: May 03, 2024
Last Updated: 09/26/2026